Latest News and Press Releases

First oral presentation of Phase 3 data evaluating the investigational use of VOQUEZNA® in Non-Erosive Reflux Disease (NERD)1New research on Erosive gastroesophageal reflux disease (GERD)...

Over 17,500 total prescriptions for VOQUEZNA® products have been dispensed, launch-to-date, a 361% increase since last quarterly report Net revenues of $1.9 million reported for the first full...

Management to host conference call on Thursday, May 9, 2024, at 8:30 a.m. ET FLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical...

FLORHAM PARK, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...

A Media Snippet accompanying this announcement is available by clicking on this link. FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...

Launched VOQUEZNA® (vonoprazan) tablets in November 2023 for the treatment of Erosive GERD (gastroesophageal reflux disease), achieving net revenues of $0.7 million for the fourth quarter Early...

Phathom Pharmaceuticals to host a conference call on Thursday, March 7, 2024, at 8:30 a.m. ET to report Q4 and full year 2023 financial results.

One of the largest pharmacy benefit management (PBM) companies in the United States has added VOQUEZNA (vonoprazan) tablets to its national formularies for commercial plans, effective immediately ...

Phathom management will participate in a fireside chat at the Guggenheim Biotechnology Conference on February 7, 2024, at 1:30 p.m. ET.

Amendment provides more favorable terms including a 14-month extension of the interest-only period and maturity date until December 2027Up to an additional $100 million in non-dilutive capital...